APA (7th ed.) Citation

P, S., DM, G., & M, M. (2026). Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. Reviews in cardiovascular medicine, 27(4), 50430. https://doi.org/10.31083/RCM50430

Chicago Style (17th ed.) Citation

P, Sabouret, Giamundo DM, and Mamas M. "Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab Vs Evolocumab." Reviews in Cardiovascular Medicine 27, no. 4 (2026): 50430. https://doi.org/10.31083/RCM50430.

MLA (9th ed.) Citation

P, Sabouret, et al. "Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab Vs Evolocumab." Reviews in Cardiovascular Medicine, vol. 27, no. 4, 2026, p. 50430, https://doi.org/10.31083/RCM50430.